Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Authors
Keywords
-
Journal
INFECTION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-19
DOI
10.1007/s15010-022-01825-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection
- (2022) Meagan P. O’Brien et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2022) Obbina Abani et al. LANCET
- Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
- (2022) Mark N. Polizzotto et al. LANCET
- Effect of convalescent plasma as complementary treatment in patients with moderate COVID ‐19 infection
- (2022) Manuel E. Baldeón et al. TRANSFUSION MEDICINE
- A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19
- (2022) Yogiraj Ray et al. Nature Communications
- Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
- (2022) Karin van den Berg et al. Scientific Reports
- High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial
- (2022) Andrea Alemany et al. Lancet Respiratory Medicine
- Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis
- (2022) Jiawen Deng et al. Future Virology
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
- (2021) Romina Libster et al. NEW ENGLAND JOURNAL OF MEDICINE
- (A Little) Clarity on Convalescent Plasma for Covid-19
- (2021) Louis M. Katz NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of convalescent plasma therapy for COVID ‐19: A systematic review and meta‐analysis
- (2021) Charan T. R. Vegivinti et al. JOURNAL OF CLINICAL APHERESIS
- Perspectives on glucocorticoid treatment for COVID-19: a systematic review
- (2021) Leonardo P. Cordeiro et al. Pharmacological Reports
- Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
- (2021) María Elvira Balcells et al. PLOS MEDICINE
- Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York
- (2021) Elliott Bennett-Guerrero et al. CRITICAL CARE MEDICINE
- A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm
- (2021) Mandana Pouladzadeh et al. Internal and Emergency Medicine
- Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Neutralizing Antibody Therapeutics for COVID-19
- (2021) Aeron C. Hurt et al. Viruses-Basel
- Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
- (2021) Manaf AlQahtani et al. Scientific Reports
- Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
- (2021) Parakkal Deepak et al. ANNALS OF INTERNAL MEDICINE
- Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study
- (2021) Benjamin Gaborit et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- First in Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients with COVID‐19
- (2021) Peter Chen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection
- (2021) Jin Yong Kim et al. CLINICAL THERAPEUTICS
- Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
- (2021) Leo Sekine et al. EUROPEAN RESPIRATORY JOURNAL
- Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
- (2021) Philippe Bégin et al. NATURE MEDICINE
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- (2021) Michael Dougan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- (2021) Frederick K. Korley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
- (2021) Arvind Gharbharan et al. Nature Communications
- COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions
- (2021) Eunice Twumwaa Tagoe et al. Frontiers in Public Health
- Efficacy of convalescent plasma for treatment of COVID-19 in Uganda
- (2021) Bruce Kirenga et al. BMJ Open Respiratory Research
- Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
- (2021) et al. ANNALS OF INTERNAL MEDICINE
- A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load
- (2021) Michael Dougan et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis
- (2021) Jiawen Deng et al. Future Virology
- Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19
- (2021) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
- (2021) Wesley H. Self et al. LANCET INFECTIOUS DISEASES
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- (2021) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- (2021) Anil Gupta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis
- (2021) J Deng et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
- (2021) Mila B. Ortigoza et al. JAMA Internal Medicine
- Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia
- (2021) Francesco Menichetti et al. JAMA Network Open
- Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
- (2021) Karin Holm et al. BMC Research Notes
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- (2020) Kelvin Kai-Wang To et al. LANCET INFECTIOUS DISEASES
- CINeMA: An approach for assessing confidence in the results of a network meta-analysis
- (2020) Adriani Nikolakopoulou et al. PLOS MEDICINE
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
- (2020) Ling Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Optimally estimating the sample standard deviation from the five‐number summary
- (2020) Jiandong Shi et al. Research Synthesis Methods
- Risk Factors for Coronavirus Disease 2019 (COVID-19)–Associated Hospitalization: COVID-19–Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System
- (2020) Jean Y Ko et al. CLINICAL INFECTIOUS DISEASES
- Risk factors for Covid-19 severity and fatality: a structured literature review
- (2020) Dominik Wolff et al. INFECTION
- Antiviral monotherapy for hospitalised patients with COVID-19 is not enough
- (2020) Bin Cao et al. LANCET
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
- (2020) Anup Agarwal et al. BMJ-British Medical Journal
- Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients
- (2020) Christel Faes et al. International Journal of Environmental Research and Public Health
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- (2020) Ventura A. Simonovich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of COVID-19 Patients at High Risk of Progression to Severe Disease
- (2020) Zhenyu Dai et al. Frontiers in Public Health
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range
- (2016) Dehui Luo et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Ranking treatments in frequentist network meta-analysis works without resampling methods
- (2015) Gerta Rücker et al. BMC Medical Research Methodology
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
- (2015) Xiang Wan et al. BMC Medical Research Methodology
- Graphical Tools for Network Meta-Analysis in STATA
- (2013) Anna Chaimani et al. PLoS One
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started